Lanreotide Therapy for Gastroenteropancreatic Neuroendocrine Tumors

Indications & Patient Selection

• Lanreotide is indicated for unresectable, well‑to‑moderately differentiated, locally advanced or metastatic gastroenteropancreatic NETs that are somatostatin‑receptor positive. The recommendation comes from the NCCN guidelines. 1

• Patients with a clinically significant tumor burden or documented disease progression and a Ki‑67 proliferative index ≤10 % are candidates for lanreotide to control tumor growth. (NCCN guideline recommendation) 2

• Non‑functioning pancreatic or intestinal NETs that are well‑to‑moderately differentiated are the specific tumor subtypes that derive antiproliferative benefit from lanreotide. (NCCN guideline) 3

• Lanreotide should not be used for poorly differentiated or high‑grade NETs (Ki‑67 > 10 %). (NCCN guideline) 2

• Benefit is expected only in somatostatin‑receptor‑positive disease, confirmed by octreotide scintigraphy (Octreoscan). (NCCN guideline) 3

Antiproliferative Efficacy

• In the phase III CLARINET trial, lanreotide significantly prolonged progression‑free survival (PFS) compared with placebo (median PFS not reached vs 18 months; hazard ratio 0.47; P < 0.001). The open‑label extension estimated a median PFS of 32.8 months. (High‑quality RCT evidence) 2

Symptom Control

• Lanreotide improves carcinoid syndrome symptoms (flushing, diarrhea); rescue octreotide was required in 34 % of lanreotide‑treated patients versus 49 % with placebo (P = 0.02). (NCCN guideline) 4

• The drug is also recommended for symptom control in patients with gastrin‑producing tumors (gastrinomas) and vasoactive intestinal peptide‑producing tumors (VIPomas). (NCCN guideline) 4

Timing of Initiation

• For asymptomatic patients with metastatic NETs and low tumor burden, the NCCN guidelines state that there is no clear consensus on when to start lanreotide; observation with periodic imaging is an acceptable approach. (Guideline uncertainty) 1

• Deferring lanreotide initiation until radiologic or clinical evidence of tumor progression may be appropriate in selected asymptomatic patients. (Guideline recommendation) 2

• In patients with progressive disease and a clinically significant tumor burden, immediate initiation of lanreotide is advised. (Guideline recommendation) 4

Monitoring for Carcinoid Heart Disease

• For symptomatic carcinoid syndrome patients, cardiology consultation and echocardiography are recommended when 5‑HIAA levels are ≥300 µmol/24 h and the patient experiences ≥3 flushing episodes per day, given a ~59 % risk of carcinoid heart disease. (NCCN guideline) 2

Lanreotide for Neuroendocrine Tumors

Clinical Applications

• The National Comprehensive Cancer Network recommends lanreotide for patients with unresectable, well to moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors 5, 6
• Lanreotide is used for both symptom control and anti-tumor effects in patients with neuroendocrine tumors, with a significant improvement in progression-free survival (PFS) compared to placebo (not reached vs 18 months; HR, 0.47; P<0.001) 6, 7
• The American College of Physicians and the National Comprehensive Cancer Network suggest that lanreotide shares the same mechanism of action as octreotide, making both appropriate options for tumor control 6

Hormone-Related Symptom Control

• The National Comprehensive Cancer Network states that lanreotide is effective for managing symptoms in patients with carcinoid syndrome, gastrinomas, and VIPomas 8

Formulation and Administration

• The standard dosing for neuroendocrine tumors is 120 mg every 4 weeks, as recommended by the National Comprehensive Cancer Network 7

Efficacy Data

• The CLARINET study demonstrated that lanreotide significantly prolonged progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors, with an estimated PFS of 32.8 months 6, 7

Side Effects and Safety Profile

• The European Society of Medical Oncology notes that lanreotide can cause gallbladder abnormalities in approximately 26% of patients 9
• The National Comprehensive Cancer Network reports that lanreotide may produce a reduction and delay in postprandial insulin secretion, resulting in transient, mild glucose intolerance, and can also cause fat malabsorption and vitamin A and D malabsorption 10

Clinical Considerations and Algorithm

• For asymptomatic patients with unresectable neuroendocrine tumors, low tumor burden, and stable disease, the National Comprehensive Cancer Network recommends consideration of observation with marker assessment and imaging every 3-12 months, or treatment with lanreotide to control tumor growth 5, 6
• For symptomatic patients with unresectable disease or clinically significant tumor burden, the National Comprehensive Cancer Network suggests initiating lanreotide 120 mg every 4 weeks, and monitoring for symptom control and tumor response 6, 7